hotspot -WSS

hotspot

author：explore 2025-09-06 01:59:31 - browse：254

Paul Biondi Flagship

Pharma giant Pfizer is turning to venture firm Flagship for new drug development, signing a deal worth up to $7 billion to mine new medicines from the latter’s portfolio companies.

Flagship and Pfizer announced Tuesday that they will each put $50 million into developing up to 10 drug candidates. Pfizer will have first rights to acquire each for up to $700 million, plus royalties. Flagship’s portfolio companies will also share in any payments that come out of the partnership.

Flagship has historically developed new medicines by forming and spinning out startup companies, some of which have signed their own collaboration deals with the likes of Amgen or Nestlé Health Science. But in recent years, the firm has been pursuing external partnerships through a new business division called Pioneering Medicines, led by former Bristol Myers Squibb executive Paul Biondi. Pioneering Medicines uses technologies and other scientific platforms being developed by Flagship’s portfolio companies to look for possible therapies in disease areas that the startup may not be working in.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： A solution to the after

entertainment

WSS

Data integrity in scientific journals requires "effort" by publishers, institutions

It's time to retire 'poor historian' from clinicians' vocabularies

Data integrity in scientific journals requires "effort" by publishers, institutions

Military medical care influenced by rank and race, new study finds

Data integrity in scientific journals requires "effort" by publishers, institutions

With competition flaring, obesity drug hits goal in liver disease study

entertainment

hotspot

focus

Walensky prepares to leave CDC — and Congress — behind

Community Health Systems hospitals under DOJ investigation

Anesthesiologist group: stop taking Ozempic before surgery

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Heart attack and stroke risk calculators need revising

It's time to retire 'poor historian' from clinicians' vocabularies

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Arc Institute generative AI designs new CRISPR systems

After affirmative action ruling, medical educators look to 'holistic review'

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

focus

Dario to buy mental health app maker Twill in cash and stock deal

The Harvard botanist who searched for psychedelics in the Amazon

NVIDIA and Google execs on the future of AI and drug discovery

Glen Campbell's doctor discusses his public struggle with Alzheimer's

A solution to the after

New documents shed light on MD Anderson Cancer Institute feud

leisure time

entertainment

focus

focus